02217nam 2200577 450 991077987300332120230803021102.01-78084-270-81-78084-271-6(CKB)2550000001101935(EBL)1179645(OCoLC)854971660(SSID)ssj0001599928(PQKBManifestationID)16306258(PQKBTitleCode)TC0001599928(PQKBWorkID)14892839(PQKB)11287715(MiAaPQ)EBC1179645(Au-PeEL)EBL1179645(EXLCZ)99255000000110193520220517d2013 uy 0engur|n|---|||||txtccrEmerging therapeutic options for hepatitis C /editors, Masao Omata, Tatsuo Kanda1st ed.London, England :Future Medicine Ltd.,[2013]©20131 online resource (117 p.)Description based upon print version of record.1-78084-272-4 Title page; Copyright page; Contents; Foreword. Hepatitis C virus infection: from discovery to eradication; 1. Interferons in clinical trials; 2. Protease inhibitors; 3. NS5A inhibitor: daclatasvir; 4. Toll-like receptor agonists for nonresponders to hepatitis C virus treatment: hope versus promise?; 5. Treatment options in HIV-HCV-coinfected patients; 6. Treatment options for dual hepatitis C/hepatitis B virus coinfection; 7. Hepatitis C virus treatment in patients with metabolic syndrome; 8. Future directions in hepatitis C therapy; IndexEmerging Therapeutic Options for Hepatitis CHepatitis CTreatmentHepatitis CChemotherapyAntiviral agentsHepatitis CTreatment.Hepatitis CChemotherapy.Antiviral agents.616.362306Omata MasaoKanda TatsuoMiAaPQMiAaPQMiAaPQBOOK9910779873003321Emerging therapeutic options for hepatitis C3763873UNINA